Digital Pathology & Imaging - software & AI news

Daily news on software, AI, and companies shaping digital pathology & imaging.

Showing 103 results
A cardiologist's hands holding a stent in an operating room

Jun 1, 2026

Andhra-Based Sri Datta Hospital Completes AI-Guided OCT Stent Implantation

Sri Datta Hospital in Andhra Pradesh has achieved a significant milestone by successfully performing the first AI-guided Optical Coherence Tomography (OCT) stent implantation in the region.This groundbreaking procedure involved the implantation of a Bio-Resorbable Scaffold (BRS) stent in a 60-year-old patient, marking a notable advancement in cardiovascular care. Dr. Krishnakanth Garlapati, a leading interventional cardiologist and the hospital's founder, conducted the operation using an innovat
A minimalist representation of a cell membrane highlighting the TROP2 biomarker in a dark color scheme.

May 31, 2026

Leica Biosystems Expands AstraZeneca And Daiichi Sankyo Collaboration To Advance AI Driven Lung Cancer Biomarker Research

Leica Biosystems is enhancing its collaboration with AstraZeneca and Daiichi Sankyo to further AI-driven research in lung cancer biomarkers, specifically targeting the TROP2 biomarker in non-small cell lung cancer.The expanded partnership aims to develop an immunohistochemistry (IHC) assay and an image analysis algorithm to evaluate the TROP2 Normalized Membrane Ratio (NMR). This initiative builds on AstraZeneca’s existing computational pathology algorithm, Quantitative Continuous Scoring (QCS),
Minimalist illustration of a liver with AI elements

May 31, 2026

Roche Holding AG stock (CH0012032048): Liver disease AI panel and diagnostics push keep Swiss shares

Roche Holding AG has garnered attention on the SIX Swiss Exchange following the introduction of an AI-enabled Liver Disease Panel by its diagnostics division. This launch is part of a broader strategy to enhance its product offerings in 2026, which is crucial for investors monitoring the company's growth trajectory and innovation in healthcare technology.The newly unveiled Liver Disease Panel leverages certified algorithms aimed at improving the management of chronic liver diseases, marking anot
A radioconjugate vial on a lab bench in a clinical setting.

May 29, 2026

Nucs AI Announces Collaboration to Develop AI-driven Response Prediction for Next-Generation Therapeutic Radioconjugates

Nucs AI has partnered with AstraZeneca to enhance predictive imaging biomarkers for therapeutic radioconjugates, specifically targeting metastatic prostate cancer.This collaboration marks a significant step in the pharmaceutical industry's exploration of AI-driven response prediction models. Nucs AI aims to adapt its existing technology to create predictive models tailored for next-generation PSMA-targeted radioconjugates. By focusing on metastatic castration-resistant prostate cancer, the partn
Flat design illustration of lung and breast cancer cells

May 29, 2026

AstraZeneca & Roche Push AI-Based Cancer Pathology Expansion Across Asia

AstraZeneca and Roche Diagnostics Asia Pacific have embarked on a significant collaboration aimed at enhancing AI-driven cancer pathology across multiple Asian countries. This three-year initiative will specifically target Singapore, Taiwan, South Korea, Thailand, Malaysia, India, Indonesia, Vietnam, and the Philippines.The partnership seeks to advance biomarker testing and facilitate more precise treatment options for patients with breast and lung cancer. AstraZeneca and Roche plan to implement
A retinal imaging device in a clinical setting, highlighting the focus on diabetic retinopathy screening.

May 29, 2026

AI-Driven Diabetic Retinopathy Screening Market is expected

The AI-driven diabetic retinopathy screening market is projected to experience significant growth, reaching an estimated value of $2.22 billion by 2033. This growth is fueled by a compound annual growth rate (CAGR) of 21% from 2026 to 2033, as the industry increasingly adopts AI technologies for early disease detection and diagnosis.The market encompasses various AI-based solutions that enhance the detection and diagnosis of diabetic retinopathy through advanced retinal imaging and automated ana
CT scanner in a dimly lit radiology room

May 29, 2026

AI-Powered Diagnostic Imaging Market Size, Share & Industry

The AI-powered diagnostic imaging market is on a significant growth trajectory, projected to reach USD 22.58 billion by 2032, expanding at a compound annual growth rate (CAGR) of 26.40% from 2026 to 2032.This expansion is fueled by a surge in demand for AI-assisted disease detection, advancements in imaging technologies, and increased investments in precision diagnostics. The integration of machine learning and computer vision into radiology is enhancing diagnostic accuracy and addressing the sh
X-ray film on a lightbox in a dimly lit radiology room

May 29, 2026

Teleradiology Market Surges as Remote Diagnostics and AI Transform Global Medical Imaging

The teleradiology market is experiencing significant growth, driven by advancements in remote diagnostics and artificial intelligence, transforming the landscape of medical imaging globally.Historically, radiology relied heavily on onsite professionals to interpret medical images such as X-rays and MRIs. However, the rise of digital communication technologies has enabled healthcare providers to transmit these images securely across vast distances, facilitating remote interpretation by expert rad
A minimalist illustration of a lung and a screening device in a dark palette.

May 29, 2026

Median Technologies: €40 Million Capital Increase Launched To Support eyonis LCS Expansion

Median Technologies has initiated a €40 million capital increase, potentially rising to €50 million, aimed at enhancing the commercial rollout of its AI-driven eyonis LCS lung cancer screening platform in the U.S. and Europe, while also expanding its capabilities to address additional cancer types.The capital increase will occur via a public offering of ordinary shares, with a reserved offering for guarantors amounting to €10 million contingent on full subscription. Median Technologies has alrea
A tissue slide in a dimly lit pathology lab, showcasing the PD-L1 biomarker analysis.

May 28, 2026

Leica Biosystems, Indica Labs, And Lunit Advance AI Powered Digital Pathology For PD L1 Biomarker Analysis

Leica Biosystems, Indica Labs, and Lunit are collaborating to enhance AI-driven digital pathology, specifically for PD-L1 biomarker analysis, aiming to streamline and standardize pathology workflows in precision oncology research.The partnership builds on an existing collaboration between Leica Biosystems and Indica Labs, now incorporating Lunit's advanced AI capabilities. This integration is set to enhance the quantification of PD-L1 and other immunohistochemistry biomarkers, providing a more c
Minimalist illustration of a prostate gland and biomarker icon

May 28, 2026

Myriad Genetics Inc stock (US62855J1043): Prolaris AI launch lifts focus

Myriad Genetics Inc. is generating renewed interest among investors following the announcement of its Prolaris + AI Test, set to launch this month. The stock was noted at $3.93, reflecting a 2.1% increase after the May 26 update.The Prolaris + AI Test represents a significant advancement in prostate cancer surveillance by integrating biomarker data with AI-driven pathology. This launch is particularly noteworthy as it positions Myriad Genetics within the competitive landscape of specialty diagno
A dual glucose-ketone sensor on a wooden table in a clinical setting.

May 28, 2026

Abbott Laboratories stock (US0028241000): regulatory clearances for AI cardiology and glucose-ketone

Abbott Laboratories has recently secured regulatory approvals for two significant digital health innovations: an AI-assisted coronary imaging platform and a dual glucose-ketone sensor, enhancing its portfolio in cardiology and diabetes care.The Ultreon 3.0 platform is designed to assist physicians during coronary stent procedures by integrating imaging and data-driven insights, while the Libre Duo sensor aims to provide comprehensive monitoring for diabetes patients by tracking both glucose and